United Therapeutics CorporationUTHRNASDAQ
Loading
Net Income Growth Under PressureDecelerating
Percentile Rank62
Year-over-Year Change
Year-over-year net income growth rate
Latest
7.56%
↓ 81% vs avg
Percentile
P62
Within normal range
Streak
1 qtr
Consecutive declineDecelerating
Average
39.41%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | 7.56% |
| Q3 2025 | 9.43% |
| Q2 2025 | -3.94% |
| Q1 2025 | 6.94% |
| Q4 2024 | -2.52% |
| Q3 2024 | 11.15% |
| Q2 2024 | -9.30% |
| Q1 2024 | 41.23% |
| Q4 2023 | -18.87% |
| Q3 2023 | 3.24% |
| Q2 2023 | 7.60% |
| Q1 2023 | 82.36% |
| Q4 2022 | -44.80% |
| Q3 2022 | 106.29% |
| Q2 2022 | -51.65% |
| Q1 2022 | 113.81% |
| Q4 2021 | -31.04% |
| Q3 2021 | -5.74% |
| Q2 2021 | 509.89% |
| Q1 2021 | -71.36% |
| Q4 2020 | -42.29% |
| Q3 2020 | 59.85% |
| Q2 2020 | -22.22% |
| Q1 2020 | 161.79% |
| Q4 2019 | -60.27% |
| Q3 2019 | -35.45% |
| Q2 2019 | 141.47% |
| Q1 2019 | -857.43% |
| Q4 2018 | -38.69% |
| Q3 2018 | -38.40% |
| Q2 2018 | -29.28% |
| Q1 2018 | 1186.84% |
| Q4 2017 | -93.12% |
| Q3 2017 | 593.39% |
| Q2 2017 | -131.35% |
| Q1 2017 | 61.92% |
| Q4 2016 | -31.83% |
| Q3 2016 | -21.49% |
| Q2 2016 | -12.48% |
| Q1 2016 | 125.05% |